09.08.2016 • News

CIA Member Survey Reveals Positive UK Outlook

A survey of its members by the UK’s Chemical Industries Association (CIA) has shown that while some investment is expected to be hit by the uncertainty post-Brexit, three-quarters of companies will maintain or increase their capital expenditure. According to the trade association, 71% of members surveyed said levels of employment would remain the same or increase. The UK’s chemical industry creates 140,000 direct jobs and supports around half a million indirect jobs, with sales approaching £50 billion in 2015, according to CIA’s figures.

Over the next twelve months, 89% of respondents said investment in R&D will stay the same or increase, 87% said they believe exports will remain unchanged or rise, and 80% said sales will grow or  remain stable. The poll, carried out after the UK voted to leave the EU, also highlighted the uncertainty over the country’s future relationship with the economic union and the exchange rate of Sterling to euro.

On a positive note, members said they saw opportunities for growth through expanded production capacity, new products coming into the market and other operational improvements. Sterling’s lower value is also expected to boost exports, a key driver of growth for the UK, although on the flip side, imports will become more expensive.

CIA’s chief executive Steve Elliott said the survey shows there is still confidence that the UK can be a good place to do business. “I hope the views of our business leaders will further support the wish for all of manufacturing to invest in the UK and the government will do all it can to make it even better for companies to invest here,” he added.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.